Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Marampon

Showing results (31-40 of 154) with videos related to

Pageof 16
Sort By:
Current Problems in Cancer|June 1, 2019
Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot studyFrancesca De Felice, Ilaria Benevento, Nadia Bulzonetti, et al.
Cancer Letters|February 17, 2019
Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperationSilvia Codenotti, Fiorella Faggi, Roberto Ronca, et al.
BJR Case Reports|August 14, 2023
Skin metastases from prostate cancer successfully treated with radiation therapyFrancesco Marampon, Martina Parisi, Piero Rodolfo Cicco, et al.
Urologic Oncology|November 14, 2024
Silent metastasis in metastatic castrate-resistant prostate cancer: a collection of two case reportsFrancesca De Felice, Elisa Vitti, Carlo Guglielmo Cattaneo, et al.
Cancers|August 29, 2024
Challenges and Opportunities in Accessing Surgery for Glioblastoma in Low-Middle Income Countries: A Narrative ReviewPaolo Tini, Giovanni Rubino, Pierpaolo Pastina, et al.
Endocrine-Related Cancer|May 10, 2011
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cellsGiovanni Luca Gravina, Francesco Marampon, Foteini Petini, et al.
Molecular Cancer|November 27, 2010
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiationGiovanni L Gravina, Claudio Festuccia, Francesco Marampon, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 30, 2015
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell modelsGiovanni Luca Gravina, Andrea Mancini, Luca Scarsella, et al.
Cell Cycle (Georgetown, Tex.)|July 3, 2008
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancyGianluca Bossi, Francesco Marampon, Revital Maor-Aloni, et al.
International Journal of Oncology|April 17, 2013
Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samplesGiovanni Luca Gravina, Andrea Mancini, Guido Ranieri, et al.
Pageof 16

Showing results (31-40 of 154) with videos related to

Sort By:
Pageof 16
Current Problems in Cancer|June 1, 2019
Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot studyFrancesca De Felice, Ilaria Benevento, Nadia Bulzonetti, et al.
Cancer Letters|February 17, 2019
Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperationSilvia Codenotti, Fiorella Faggi, Roberto Ronca, et al.
BJR Case Reports|August 14, 2023
Skin metastases from prostate cancer successfully treated with radiation therapyFrancesco Marampon, Martina Parisi, Piero Rodolfo Cicco, et al.
Urologic Oncology|November 14, 2024
Silent metastasis in metastatic castrate-resistant prostate cancer: a collection of two case reportsFrancesca De Felice, Elisa Vitti, Carlo Guglielmo Cattaneo, et al.
Cancers|August 29, 2024
Challenges and Opportunities in Accessing Surgery for Glioblastoma in Low-Middle Income Countries: A Narrative ReviewPaolo Tini, Giovanni Rubino, Pierpaolo Pastina, et al.
Endocrine-Related Cancer|May 10, 2011
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cellsGiovanni Luca Gravina, Francesco Marampon, Foteini Petini, et al.
Molecular Cancer|November 27, 2010
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiationGiovanni L Gravina, Claudio Festuccia, Francesco Marampon, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 30, 2015
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell modelsGiovanni Luca Gravina, Andrea Mancini, Luca Scarsella, et al.
Cell Cycle (Georgetown, Tex.)|July 3, 2008
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancyGianluca Bossi, Francesco Marampon, Revital Maor-Aloni, et al.
International Journal of Oncology|April 17, 2013
Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samplesGiovanni Luca Gravina, Andrea Mancini, Guido Ranieri, et al.
Pageof 16